Connect Biopharma Holdings (CNTB) Share-based Compensation (2024 - 2026)

Connect Biopharma Holdings (CNTB) has reported Share-based Compensation for 3 consecutive years, with $1.2 million the latest figure, recorded in Q1 2026.

• Quarterly Share-based Compensation rose 27.28% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.0 million (down 37.32% YoY) and the FY2025 annual result came in at $3.7 million, down 44.62% from the prior year.
• Share-based Compensation advanced to $1.2 million in Q1 2026 per CNTB's latest filing, from $917000.0 in the prior quarter.
• Over the last five years, Share-based Compensation for CNTB reached as high as $2.0 million in Q3 2024 and fell as low as $916000.0 in Q3 2025.
• A 3-year average of $1.3 million and a median of $1.2 million in 2026 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2025 — Share-based Compensation tumbled 54.7% — and 2026, when it gained 27.28%.
• Year by year, Share-based Compensation stood at $1.4 million in 2024, then sank by 34.55% to $917000.0 in 2025, then jumped by 30.75% to $1.2 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $1.2 million, $917000.0, and $916000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.